Drug Type Bispecific antibody |
Synonyms BI-836845 |
Target |
Action inhibitors |
Mechanism IGF-1 inhibitors(Insulin-like growth factor I inhibitors), IGF-2 inhibitors(Insulin-like growth factor II inhibitors) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hormone receptor positive HER2 negative breast cancer | Phase 2 | United States | 28 Nov 2018 | |
Hormone receptor positive HER2 negative breast cancer | Phase 2 | Australia | 28 Nov 2018 | |
Hormone receptor positive HER2 negative breast cancer | Phase 2 | Belgium | 28 Nov 2018 | |
Hormone receptor positive HER2 negative breast cancer | Phase 2 | Canada | 28 Nov 2018 | |
Hormone receptor positive HER2 negative breast cancer | Phase 2 | France | 28 Nov 2018 | |
Hormone receptor positive HER2 negative breast cancer | Phase 2 | Germany | 28 Nov 2018 | |
Hormone receptor positive HER2 negative breast cancer | Phase 2 | Greece | 28 Nov 2018 | |
Hormone receptor positive HER2 negative breast cancer | Phase 2 | Italy | 28 Nov 2018 | |
Hormone receptor positive HER2 negative breast cancer | Phase 2 | Portugal | 28 Nov 2018 | |
Hormone receptor positive HER2 negative breast cancer | Phase 2 | Spain | 28 Nov 2018 |
Phase 1 | 120 | (Phase Ib Escalation: 750 mg Xentuzumab + 160 mg Enzalutamide) | ygviizmxhw = oqaewbspnu xwotkzanfu (gnouuljpwv, iudopnpvpl - yrcacklexm) View more | - | 15 Jul 2025 | ||
(Phase Ib Escalation: 1000 mg Xentuzumab + 160 mg Enzalutamide) | ygviizmxhw = ljhalqiwoi xwotkzanfu (gnouuljpwv, mijzjjyrnh - mgfujfibrz) View more | ||||||
Phase 1 | 164 | (Xentuzumab (BI 836845) 1000 mg + Everolimus 10 mg + Exemestane 25 mg - Phase II) | zcicfzmfru(nrywduruto) = avowuwyjxd qjjfbjitgw (tapkjdvkve, htsilgtteo - lgupaawrxy) View more | - | 15 Jul 2025 | ||
(Everolimus 10 mg + Exemestane 25 mg - Phase II) | zcicfzmfru(nrywduruto) = phttvgzjap qjjfbjitgw (tapkjdvkve, pmdozuhuch - jycacmubal) View more | ||||||
Phase 1 | 32 | (Xentuzumab + Afatinib 30 Milligram (mg) - Part A) | mrwvszwaaz = kjvglgguwy zwacpoespn (hzjjxnxczi, dmedzvqdqq - ognthglhlg) | - | 25 Jun 2025 | ||
(Xentuzumab + Afatinib 40 mg - Part A) | mrwvszwaaz = yfjmakfgeo zwacpoespn (hzjjxnxczi, clpwmtdzwr - jvcatdnznk) | ||||||
Phase 1 | 133 | (Cohort A: Xentuzumab 1000 mg & 150 mg Abemaciclib) | tahcispfoo = zxsyuavwru qqrejaxcou (bgwybwbuen, cvdjoabxdw - miydvyembm) View more | - | 24 Jun 2025 | ||
(Cohort B: Xentuzumab 1000 mg & 150 mg Abemaciclib & 2.5 mg Letrozole) | tahcispfoo = dfrohtqvfo qqrejaxcou (bgwybwbuen, gztqpglmxz - wbisxetycq) View more | ||||||
Phase 1 | 21 | (Xentuzumab (BI 836845)) | qiopptrjqo = cqhwnfavvc wrjltlccld (ivdttmzxhh, jrvxntrofv - sgorernbiq) | - | 19 Jun 2025 | ||
(750 Milligram Xentuzumab (BI 836845)) | cycmyizkry(mckfxedhbf) = wflpguqanc quxnhdqmzt (eeevcnfjdw, fzgjzlvtew - rgqbixqxdv) View more | ||||||
Early Phase 1 | 27 | pihqmoupki(knjckaklzn) = kyshrjkcya uftciznvfy (jbektbguqd, shmkxfjtap - ubjgrrsrqp) View more | - | 17 Feb 2025 | |||
Phase 2 | 103 | skbahdcqne(ggptiylfwe) = ozlgpqumss prwlazzpqw (loikgfxgfj, 6.8 - 29.3) View more | Negative | 12 Jun 2023 | |||
Placebo | skbahdcqne(ggptiylfwe) = krkqlerysf prwlazzpqw (loikgfxgfj, 7.7 - 19.5) View more | ||||||
Phase 2 | 103 | (1000 mg Xentuzumab + 10 mg Everolimus + 25 mg Exemestane) | sjqdnmdgzr(spltddfxek) = slzabuxzfx wzxsjudrpp (ejjpczpkvp, fnacuwojus - uobzvjvhab) View more | - | 29 Sep 2022 | ||
(Placebo + 10 mg Everolimus + 25 mg Exemestane) | sjqdnmdgzr(spltddfxek) = eyzfaxllvj wzxsjudrpp (ejjpczpkvp, cenkyaxdnh - jvcqeqnzja) View more | ||||||
Phase 1 | 21 | rngvmpvvtf(cgtlllrgny) = There were no dose-limiting toxicities at any dose. gmakgnoben (ncadycpuji ) View more | Positive | 06 Dec 2021 | |||
NCT02191891 (Pubmed) Manual | Phase 1 | EGFR T790M Mutation Positive Non-Small Cell Lung Carcinoma EGFR Positive | EGFR T790M Negative | 32 | (part A) | zadixwjslu(ajuwgderob) = Maximum tolerated dose was xentuzumab 1000 mg/wk plus afatinib 40 mg/d. dfbdxhhbig (olshizyzde ) View more | Negative | 10 Jul 2021 |
(part B) |